STAT Plus Exclusive Eli Lilly to allow more patients to apply for special access to unapproved obesity drug Doctors seeking early access to unapproved retatrutide after Lilly granted drug to 79-year-old patient Manage alerts for this articl
STAT Plus
Exclusive Eli Lilly to allow more patients to apply for special access to unapproved obesity drug Doctors seeking early access to unapproved retatrutide after Lilly granted drug to 79-year-old patient Manage alerts for this article By Lizzy Lawrence and Elaine Chen Aug.
3, 2026 Lizzy Lawrence email protected Lizzy leads STAT’s coverage of the FDA.
Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health.
Confidential tips can be sent on Signal at lizzylaw.53.
Elaine Chen email protected Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector.
She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.
You can reach Elaine on Signal at elaineywchen.70.
Six weeks after STAT reported that Eli Lilly granted a single 79-year-old patient special access to retatrutide, an unapproved obesity drug, the company confirmed on Monday that it will allow other patients to apply for early access.
The announcement comes after STAT asked Lilly about the requests for expanded access from a handful of doctors who had not yet received a reply from the drugmaker.
It marks a striking change in the public posture of the pharmaceutical giant, which had previously offered little information about the special access program.
“For a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial, we believe it is medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA’s guidance,” a Lilly spokesperson told STAT.
The company said it is actively reviewing requests from health care providers.
STAT+ Exclusive Story Already have an account?
Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account?
Log in Individual plans Group plans Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%
Request A Quote Request A Quote Savings start at 25%
2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.
Log In biotechnology, drug development, FDA, Pharmaceuticals, Policy, STAT+ Submit a correction requestReprints Lizzy Lawrence FDA Reporter Lizzy leads STAT’s coverage of the FDA.
Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health.
Confidential tips can be sent on Signal at lizzylaw.53.
Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector.
She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.
You can reach Elaine on Signal at elaineywchen.70.
Newsletter The latest updates in federal health agencies, research institutes, and U.S.
policy The Readout August 3, 2026 STAT Plus: Is there a pharma mega-merger in the making?
Biotech August 3, 2026 STAT Plus: BioNTech names Guido Oelkers its new CEO First Opinion July 31, 2026 Limb girdle muscular dystrophy patients face a maddening reality Biotech July 30, 2026 STAT Plus: FDA expert committee votes in favor of Replimune’s melanoma treatment Biotech July 29, 2026 STAT Plus: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
Peptides referenced: Retatrutide.
Related reading: What’s behind the peptide boom and why it matters to Switzerland - SWI swissinfo.ch, Peptide Therapy for Weight Loss Record Includes FC Bayern Text, The Best Peptide Beauty Products for Firmer, Hydrated Skin, According to Dermatologists, Qnovia licenses novel antimicrobial peptide.